Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer owned 1,654,597 shares in the company, valued at $43,830,274.53. This represents a 10.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $21.92, for a total value of $4,384,000.00.
• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total transaction of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total transaction of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.85, for a total transaction of $4,170,000.00.

Roivant Sciences Stock Up 1.4%

Roivant Sciences stock traded up $0.39 on Wednesday, hitting $27.48. The company’s stock had a trading volume of 5,125,374 shares, compared to its average volume of 6,849,505. The firm has a market cap of $19.67 billion, a P/E ratio of -23.49 and a beta of 1.22. The company has a fifty day moving average price of $22.95 and a 200-day moving average price of $18.62. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $27.94.

Institutional Trading of Roivant Sciences

Several institutional investors and hedge funds have recently modified their holdings of ROIV. Penn Davis Mcfarland Inc. lifted its position in shares of Roivant Sciences by 10.1% in the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock worth $28,173,000 after purchasing an additional 170,456 shares during the period. Valeo Financial Advisors LLC acquired a new position in Roivant Sciences in the second quarter valued at $1,145,000. IFG Advisory LLC bought a new position in shares of Roivant Sciences in the 2nd quarter worth about $255,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Roivant Sciences in the 2nd quarter valued at about $3,064,000. Finally, Franklin Resources Inc. bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at about $997,000. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on ROIV shares. HC Wainwright boosted their price objective on shares of Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Jefferies Financial Group restated a “buy” rating and set a $30.00 target price on shares of Roivant Sciences in a report on Monday, February 9th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Leerink Partners boosted their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Guggenheim raised their price objective on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.